Meta-analyses demonstrate that both GLP-1RAs and SGLT2i reduce the risk of major adverse cardiovascular events (MACE) to a comparable extent, while SGLT2i provide superior benefits in mitigating hospitalization for heart failure and slowing chronic kidney disease progression
ShiodaTKatoHOhnishiYTashiroKIkegawaMNakayamaEEet al
Recent research demonstrated that the distinct insulinotropic potential of incretins in diabetes is highlighted by a Gs/Gq signaling shift in pancreatic -cells chronically exposed to high glucose 41
There are so many gorgeous women in my brokerage, says Reynolds
For GLP-1 medications like Semaglutide or Tirzepatide, the safest programs are provider-led, transparent about pricing, and clear about medication source, dosing, labs, and ongoing access
Oral GLP-1s represent meaningful progress, offering more flexibility for patients who prefer a non-injectable treatment